Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing
K.C. Allen Chan(Rubicon Biotechnology (United States)), Yuk Ming Dennis Lo(Chinese University of Hong Kong), Wing Cheong Chan, Henry Lik‐Yuen Chan(Radiant Research (United States)), John Wong(Chinese University of Hong Kong), Rossa W. K. Chiu(Chinese University of Hong Kong), Edwin P. Hui(Johns Hopkins University), Stephen L. Chan(Chinese University of Hong Kong), Simon S.M. Ng(Chinese University of Hong Kong), Sze Chuen Cesar Wong(Hong Kong Polytechnic University), Kun Sun(Wenzhou Medical University), Anthony T.�C. Chan(Chinese University of Hong Kong), David S.C. Hui(Chinese University of Hong Kong), Peiyong Jiang(Chinese University of Hong Kong), Brigette Ma(Chinese University of Hong Kong), Hao Sun(Guangzhou Institutes of Biomedicine and Health), Carol W. M. Chan(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 470
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Coronaviruses — drug discovery and therapeutic options
|Nature Reviews Drug Discovery|2016|1.8k